Spots Global Cancer Trial Database for Post Transplant Donor Lymphocyte Infusion

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Post Transplant Donor Lymphocyte Infusion

Official Title: Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant

Study ID: NCT00167180

Conditions

Leukemia, Myeloid, Chronic

Lymphomas

Multiple Myeloma

Myelodysplastic Syndrome

Leukemia, Lymphocytic, Acute

Leukemia, Lymphocytic, Chronic

AML

Interventions

Donor Lymphocyte Infusion

Induction Chemotherapy

Study Description

Brief Summary: The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.

Detailed Description: When cancer relapses after donor bone marrow transplantation, regular dose chemotherapy offers little hope of prolonged survival. However, there is evidence that lymphocytes can attack cancer cells. There is considerable evidence that this immune attack on cancer cells is associated with graft-versus-host disease. Although graft-versus-host disease can cause problems, this immune reaction may, in part, be the way that bone marrow transplantation cures cancer. In this study we hope that infusion of immune cells from the subject's bone marrow donor plus a chemotherapy regimen of cyclophosphamide and fludarabine will activate the subject's immune system to attack their cancer.